GSK plc (GSK.L)
| Previous close | 1,609.50 |
| Open | 1,605.00 |
| Bid | 1,602.00 x 0 |
| Ask | 1,602.50 x 0 |
| Day's range | 1,595.50 - 1,612.00 |
| 52-week range | 1,371.40 - 1,823.50 |
| Volume | |
| Avg. volume | 6,961,782 |
| Market cap | 65.427B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 14.19 |
| EPS (TTM) | 1.13 |
| Earnings date | 30 Oct 2024 |
| Forward dividend & yield | 0.60 (3.73%) |
| Ex-dividend date | 15 Aug 2024 |
| 1y target est | N/A |
Simply Wall St.GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic Alliances, and New Vaccine Launches
GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with a significant decline in U.S. vaccine sales and ongoing legal issues. In the discussion that follows, we will delve into GSK's financial health, operational inefficiencies, strategic growth initiatives, and external threats to provide a comprehensive overview of the company's current business situation.
Business WireGSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
PHILADELPHIA, September 18, 2024--GSK announces positive topline data on co-administration of AREXVY and SHINGRIX
PR NewswireBrooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk
GSK plc (LSE/NYSE: GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to encourage people 50 and older to embrace and protect the power they've found in aging by asking their doctor or pharmacist about their risk for shingles and about vaccination.
